BE900119A - Proteines humaines, antisera et necessaires experimentaux. - Google Patents

Proteines humaines, antisera et necessaires experimentaux.

Info

Publication number
BE900119A
BE900119A BE0/213302A BE213302A BE900119A BE 900119 A BE900119 A BE 900119A BE 0/213302 A BE0/213302 A BE 0/213302A BE 213302 A BE213302 A BE 213302A BE 900119 A BE900119 A BE 900119A
Authority
BE
Belgium
Prior art keywords
antisera
proteins
experimental
necessary
human proteins
Prior art date
Application number
BE0/213302A
Other languages
English (en)
Inventor
M K Dr Fagerhol
I Dr Dale
I Naesgaard
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of BE900119A publication Critical patent/BE900119A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/803—Physical recovery methods, e.g. chromatography, grinding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808—Automated or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne les deux protéines L1 granulocytaires humaines pures de pI 6.3 et 6.5, et leurs mélanges, des procédés pour leur isolement et leur purification, leur application comme protéines marqueuses et corps antigéniques, les antisera produits contre ces protéines, les procédés pour produire lesdits antisera, l'application desdits antisera pour la détermination qualitative et quantitative des protéines L1, et les nécessaires expérimentaux comprenant lesdits antisera.
BE0/213302A 1983-07-11 1984-07-09 Proteines humaines, antisera et necessaires experimentaux. BE900119A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB838318754A GB8318754D0 (en) 1983-07-11 1983-07-11 Human proteins anti-sera test kits

Publications (1)

Publication Number Publication Date
BE900119A true BE900119A (fr) 1985-01-09

Family

ID=10545560

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/213302A BE900119A (fr) 1983-07-11 1984-07-09 Proteines humaines, antisera et necessaires experimentaux.

Country Status (11)

Country Link
US (1) US4833074A (fr)
JP (2) JPH0784479B2 (fr)
BE (1) BE900119A (fr)
CH (1) CH661048A5 (fr)
DE (1) DE3425186C2 (fr)
DK (1) DK169439B1 (fr)
FR (1) FR2550205B1 (fr)
GB (2) GB8318754D0 (fr)
IT (1) IT1177889B (fr)
NL (1) NL192456C (fr)
SE (1) SE500219C2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263072B1 (fr) * 1986-10-03 1994-03-23 Ciba-Geigy Ag Peptides analogues au lymphokine
JPH023698A (ja) * 1988-06-20 1990-01-09 Denki Kagaku Kogyo Kk ヒトリンホトキシンに対するモノクローナル抗体及びそれら抗体を産生するハイブリドーマ、並びにそれら抗体を用いたヒトリンホトキシンの精製方法、測定方法及び測定試薬
US5211937A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5776348A (en) * 1995-02-07 1998-07-07 Massachusetts Institute Of Technology Mineral precipitation system and method for inhibiting mineral precipitate formation
ATE278964T1 (de) 1996-11-01 2004-10-15 Magne K Fagerhol Verfahren zur proteinextraktion
ZA981370B (en) * 1997-02-20 1998-09-07 Cerberus Developments Bv Method and apparatus for continuous flow isoelectric focusing for purifying biological substances
EP1100828B1 (fr) * 1998-07-22 2008-04-16 Sapporo Breweries Ltd. Procedes d'obtention d'anticorps agissant contre des bacteries lactiques alterant la biere et leur utilisation a des fins diagnostiques
GB0229747D0 (en) * 2002-12-20 2003-01-29 Axis Shield Asa Assay
WO2004084928A1 (fr) 2003-03-28 2004-10-07 UNIVERSITé LAVAL Proteine s100 utilisee en tant qu'activateur des neutrophiles pour attenuer la neutropenie dans le traitement du cancer
US7501256B2 (en) * 2004-07-23 2009-03-10 Aspenbio Pharma, Inc. Methods and devices for diagnosis of appendicitis
US7659087B2 (en) * 2004-07-23 2010-02-09 Aspenbio Pharma, Inc. Methods and devices for diagnosis of appendicitis
EP2352762A1 (fr) * 2008-11-03 2011-08-10 Schering Corporation Biomarqueurs de maladie inflammatoire de l'intestin et procédés apparentés du traitement
DK2563805T3 (da) * 2010-04-29 2020-05-18 Baxalta GmbH Oprensningsfremgangsmåde til divalente kationbindende proteiner på anionbytningsresin
KR20180063127A (ko) 2015-09-17 2018-06-11 암젠 인크 Il23 경로 바이오마커를 사용한, il23-길항제에 대한 임상 반응의 예측
CN108472367A (zh) 2015-12-22 2018-08-31 美国安进公司 作为对il23拮抗剂的临床应答的预测因子的ccl20
EP3622293A1 (fr) 2017-05-09 2020-03-18 Immundiagnostik AG Procédé de détermination de membre de la famille s100 de protéines liant le calcium par immunoturbidimétrie

Also Published As

Publication number Publication date
NL192456B (nl) 1997-04-01
JPH07278194A (ja) 1995-10-24
JPH0784479B2 (ja) 1995-09-13
JP2558442B2 (ja) 1996-11-27
DK338484D0 (da) 1984-07-10
FR2550205B1 (fr) 1989-12-08
DK338484A (da) 1985-01-12
GB2143239A (en) 1985-02-06
DK169439B1 (da) 1994-10-31
SE8403630L (sv) 1985-01-12
IT8448540A0 (it) 1984-07-10
JPS6051113A (ja) 1985-03-22
FR2550205A1 (fr) 1985-02-08
US4833074A (en) 1989-05-23
SE500219C2 (sv) 1994-05-09
DE3425186A1 (de) 1985-01-24
SE8403630D0 (sv) 1984-07-09
CH661048A5 (de) 1987-06-30
GB8318754D0 (en) 1983-08-10
NL8402182A (nl) 1985-02-01
GB8417338D0 (en) 1984-08-08
NL192456C (nl) 1997-08-04
IT1177889B (it) 1987-08-26
GB2143239B (en) 1987-11-11
DE3425186C2 (de) 1995-04-20

Similar Documents

Publication Publication Date Title
BE900119A (fr) Proteines humaines, antisera et necessaires experimentaux.
EP1106183A3 (fr) Anticorps contre erbB2 et leurs utilisations thérapeutiques
ATE57392T1 (de) Neue monoklonale antikoerper und hybridoma-zellen, verfahren zu ihrer herstellung und ihre anwendungen.
EP1308461A3 (fr) Anticorps contre des bèta-amyloides ou leurs dérivés, et leurs utilisations
IE830227L (en) Pyrazolooxazines
ES520988A0 (es) Procedimiento para la preparacion de nuevos 6,11-dihidro-dibenzo-(b,e)-tiepin-11-n-alcohilnorescopin-eteres.
DK173883D0 (da) Substituerede 8-phenylxanthiner
IL58775A0 (en) Hydroxyethyl-azole compounds,their production and pharmaceutical compositions containing them
ATE38036T1 (de) Benzothiophenderivate als bronchodilatoren.
IL64292A (en) D-homoandrostane-17alpha-carboxylic acids,derivatives thereof and 17alpha-spiroethers,their manufacture and pharmaceutical compositions containing them
EP0350690A3 (fr) Neutralisation des propriétés toxiques in vitro et in vivo du TNF-alfa par anticorps monoclonaux et fragments dérivés
AU4011300A (en) Compositions and methods for the treatment of immune related diseases
WO1999014241A3 (fr) Traitement d'affections liees aux fonctions immunitaires et compositions correspondantes
AU5933080A (en) 1-alkadienyl-2hydroxymethyl-3,4,5-trihydroxy- piperidine compounds
FR2560212B1 (fr) Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
MXPA03007992A (es) Composicion farmaceutica de fragmentos f(ab)2 de anticuerpos y un proceso para su preparacion
ATE17007T1 (de) Neue o-alkyl-o-carbamoyl-glycero-phosphocholine und verfahren zu ihrer herstellung.
WO2000015797A3 (fr) Compositions et methodes de traitement des maladies relatives au syteme immunitaire
ES488301A0 (es) Procedimiento para la obtencion de dehidropeptidos
UA37217C2 (uk) Аналоги 15-дезоксиспергуаліну, спосіб їх одержання, фармацевтична композиція та проміжні сполуки
FR2571146B1 (fr) Antigenes carcino-foetaux du pancreas humain et un procede de purification, antiserum contre ces antigenes et son procede de preparation et compositions diagnostiques les contenant
IL59768A0 (en) New prostaglandin derivatives in the 6-keto-pge series
FR2646607B1 (fr) Anticorps monoclonaux anti-b2 microglobuline
IT8521691A0 (it) Procedimento per la separazione dei diastero-isomeri dello zearalanol.
SE9604439D0 (sv) New receptor

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: *FAGERHOL MAGNE K. & *DALE INGE

Effective date: 20040709